Novel therapeutic approaches for the treatment of castration-resistant prostate cancer

Journal of Steroid Biochemistry and Molecular Biology

Volumn 138, Issue , 2013, Pages 248-256

  Heidegger, Isabel ^a   Massoner, Petra ^a   Eder, Iris E ^a   Pircher, Andreas ^a   Pichler, Renate ^a   Aigner, Friedrich ^a   Bektic, Jasmin ^a   Horninger, Wolfgang ^a   Klocker, Helmut ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Androgen receptor; Bone metastasis angiogenesis; Castration resistant prostate cancer; Chemotherapy; Growth factor receptor inhibitors; Immunotherapy; Radiotherapy

Indexed keywords

ABIRATERONE ACETATE; AFLIBERCEPT; ANTINEOPLASTIC AGENT; ATRASENTAN; BEVACIZUMAB; BICALUTAMIDE; CABAZITAXEL; CABOZANTINIB; CETUXIMAB; DENOSUMAB; DOCETAXEL; ENZALUTAMIDE; ERLOTINIB; FIGITUMUMAB; FLUTAMIDE; GEFITINIB; IMATINIB; IPILIMUMAB; LAPATINIB; LENALIDOMIDE; MITOXANTRONE; MONOCLONAL ANTIBODY; ORTERONEL; PREDNISONE; SIPULEUCEL T; SORAFENIB; SUNITINIB; THALIDOMIDE; TRC 105; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIBOTENTAN;

ANDROGEN SYNTHESIS; ANGIOGENESIS; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CONSTIPATION; DEEP VEIN THROMBOSIS; DRUG BINDING; DRUG MECHANISM; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; HORMONE SYNTHESIS; HUMAN; KIDNEY CANCER; MULTIMODALITY CANCER THERAPY; MULTIPLE CANCER; NEUROENDOCRINE TUMOR; NEUROPATHY; OSTEOCLAST ACTIVITY; PANCREAS TUMOR; TESTOSTERONE SYNTHESIS; UNSPECIFIED SIDE EFFECT;

ANDROGEN RECEPTOR; AR; BONE METASTASIS ANGIOGENESIS; CASTRATION-RESISTANT PROSTATE CANCER; CHEMOTHERAPY; CRPC; ENDOTHELIN; ET; GROWTH FACTOR RECEPTOR INHIBITORS; IGF; IMMUNOTHERAPY; INSULIN-LIKE GROWTH FACTOR; OS; OVERALL SURVIVAL; PCA; PDGFR; PFS; PLATELET-DERIVED GROWTH FACTOR RECEPTOR; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATE-SPECIFIC ANTIGEN; PSA; RADIOTHERAPY; RANK LIGAND; RANK-L; SD; STABLE DISEASE; TKI; TYROSINE KINASE INHIBITOR; VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR; VEGF; VEGFR;

CASTRATION; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, GROWTH FACTOR;

EID: 84885926441     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2013.06.002     Document Type: Article

References (94)

1. A. Heidenreich, J. Bellmunt, M. Bolla, S. Joniau, M. Mason, V. Matveev, N. Mottet, H.P. Schmid, K.T. van der, T. Wiegel, and F. Zattoni EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease Actas Urológicas Españolas 35 2011 501 514
2. H. Beltran, T.M. Beer, M.A. Carducci, J. de Bono, M. Gleave, M. Hussain, W.K. Kelly, F. Saad, C. Sternberg, S.T. Tagawa, and I.F. Tannock New therapies for castration-resistant prostate cancer: efficacy and safety European Urology 60 2011 279 290
3. V. Pagliarulo, S. Bracarda, M.A. Eisenberger, N. Mottet, F.H. Schroder, C.N. Sternberg, and U.E. Studer Contemporary role of androgen deprivation therapy for prostate cancer European Urology 61 2012 11 25
4. N. Mottet, J. Bellmunt, M. Bolla, S. Joniau, M. Mason, V. Matveev, H.P. Schmid, K.T. van der, T. Wiegel, F. Zattoni, and A. Heidenreich EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer European Urology 59 2011 572 583
5. Z. Culig, H. Klocker, G. Bartsch, and A. Hobisch Androgen receptors in prostate cancer Endocrine-Related Cancer 9 2002 155 170 (Pubitemid 35175976)
6. Z. Culig, H. Klocker, G. Bartsch, and A. Hobisch Androgen receptor mutations in carcinoma of the prostate: significance for endocrine therapy American Journal of Pharmacogenomics 1 2001 241 249
7. I.E. Eder, Z. Culig, T. Putz, C. Nessler-Menardi, G. Bartsch, and H. Klocker Molecular biology of the androgen receptor: from molecular understanding to the clinic European Urology 40 2001 241 251 (Pubitemid 34701893)
8. C. Huggins, and C.V. Hodges Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate CA Cancer Journal for Clinics 22 1972 232 240
9. D. Wang, and D.J. Tindall Androgen action during prostate carcinogenesis Methods in Molecular Biology 776 2011 25 44
10. S.M. Green, E.A. Mostaghel, and P.S. Nelson Androgen action and metabolism in prostate cancer Molecular and Cellular Endocrinology 360 2012 3 13
11. R. Ferraldeschi, C. Pezaro, V. Karavasilis, and J. de Bono Abiraterone and novel antiandrogens overcoming castration resistance in prostate cancer Annual Review of Medicine 64 2012 1 13
12. J.L. Mohler, C.W. Gregory, O.H. Ford III, D. Kim, C.M. Weaver, P. Petrusz, E.M. Wilson, and F.S. French The androgen axis in recurrent prostate cancer Clinical Cancer Research 10 2004 440 448 (Pubitemid 38173980)
13. G. Attard, C.S. Cooper, and J.S. De Bono Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 16 2009 458 462
14. N. Mitsiades, C.C. Sung, N. Schultz, D.C. Danila, B. He, V.K. Eedunuri, M. Fleisher, C. Sander, C.L. Sawyers, and H.I. Scher Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors Cancer Research 72 2012 6142 6152
15. N. Nadiminty, and A.C. Gao Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives World Journal of Urology 30 2012 287 295
16. S. Haile, and M.D. Sadar Androgen receptor and its splice variants in prostate cancer Cellular and Molecular Life Sciences 68 2011 3971 3981
17. K.K. Waltering, A. Urbanucci, and T. Visakorpi Androgen receptor (AR) aberrations in castration-resistant prostate cancer Molecular and Cellular Endocrinology 360 2012 38 43
18. G. Attard, and J.S. De Bono Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients Clinical Cancer Research 17 2011 3867 3875
19. A.H. Reid, G. Attard, E. Barrie, and J.S. De Bono CYP17 inhibition as a hormonal strategy for prostate cancer Nature Clinical Practice Urology 5 2008 610 620
20. M. Acharya, M. Gonzalez, G. Mannens, R. De Vries, C. Lopez, T. Griffin, and N. Tran A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects Xenobiotica 43 2013 379 389
21. Zytiga prescibe information Ref Type Magazine Article 2013 www.zytiga.com
22. S.E. Barrie, G.A. Potter, P.M. Goddard, B.P. Haynes, M. Dowsett, and M. Jarman Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase) Journal of Steroid Biochemistry and Molecular Biology 50 1994 267 273 (Pubitemid 24309119)
23. G. Turitto, M. Di Bisceglie, L. Moraca, N. Sasso, C. Sepede, A. Suriano, and S. Romito Abiraterone acetate: a novel therapeutic option in hormone-refractory prostate cancer Recenti Progressi in Medicina 103 2012 74 78
24. J.S. De Bono, C.J. Logothetis, A. Molina, K. Fizazi, S. North, L. Chu, K.N. Chi, R.J. Jones, O.B. Goodman, F. Saad Jr., J.N. Staffurth, P. Mainwaring, S. Harland, T.W. Flaig, T.E. Hutson, T. Cheng, H. Patterson, J.D. Hainsworth, C.J. Ryan, C.N. Sternberg, S.L. Ellard, A. Flechon, M. Saleh, M. Scholz, E. Efstathiou, A. Zivi, D. Bianchini, Y. Loriot, N. Chieffo, T. Kheoh, C.M. Haqq, and H.I. Scher Abiraterone and increased survival in metastatic prostate cancer New England Journal of Medicine 364 2011 1995 2005
25. C.J. Ryan, M.R. Smith, J.S. De Bono, A. Molina, C.J. Logothetis, P. de Souza, K. Fizazi, P. Mainwaring, J.M. Piulats, S. Ng, J. Carles, P.F. Mulders, E. Basch, E.J. Small, F. Saad, D. Schrijvers, H. Van Poppel, S.D. Mukherjee, H. Suttmann, W.R. Gerritsen, T.W. Flaig, D.J. George, E.Y. Yu, E. Efstathiou, A. Pantuck, E. Winquist, C.S. Higano, M.E. Taplin, Y. Park, T. Kheoh, T. Griffin, H.I. Scher, and D.E. Rathkopf Abiraterone in metastatic prostate cancer without previous chemotherapy New England Journal of Medicine 368 2013 138 148
26. P. Ferrari, G. Castagnetti, G. Ferrari, B. Baisi, and A. Dotti Combination treatment versus LHRH alone in advanced prostatic cancer Urologia Internationalis 56 Suppl. 1 1996 13 17 (Pubitemid 26149615)
27. Y.K. Lau, M.K. Chadha, A. Litwin, and D.L. Trump A dramatic, objective antiandrogen withdrawal response: case report and review of the literature Journal of Hematology & Oncology 1 2008 21
28. C.E. Bohl, W. Gao, D.D. Miller, C.E. Bell, and J.T. Dalton Structural basis for antagonism and resistance of bicalutamide in prostate cancer Proceedings of the National Academy of Sciences of the United States of America 102 2005 6201 6206 (Pubitemid 40594278)
29. B. Sahu, M. Laakso, K. Ovaska, T. Mirtti, J. Lundin, A. Rannikko, A. Sankila, J.P. Turunen, M. Lundin, J. Konsti, T. Vesterinen, S. Nordling, O. Kallioniemi, S. Hautaniemi, and O.A. Janne Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer EMBO Journal 30 2011 3962 3976
30. S. Belikov, C. Oberg, T. Jaaskelainen, V. Rahkama, J.J. Palvimo, and O. Wrange FoxA1 corrupts the antiandrogenic effect of bicalutamide but only weakly attenuates the effect of MDV3100 (Enzalutamide) Molecular and Cellular Endocrinology 365 2013 95 107
31. C. Tran, S. Ouk, N.J. Clegg, Y. Chen, P.A. Watson, V. Arora, J. Wongvipat, P.M. Smith-Jones, D. Yoo, A. Kwon, T. Wasielewska, D. Welsbie, C.D. Chen, C.S. Higano, T.M. Beer, D.T. Hung, H.I. Scher, M.E. Jung, and C.L. Sawyers Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 324 2009 787 790
32. D. Mukherji, C.J. Pezaro, and J.S. De Bono MDV3100 for the treatment of prostate cancer Expert Opinion on Investigational Drugs 21 2012 227 233
33. H.I. Scher, T.M. Beer, C.S. Higano, A. Anand, M.E. Taplin, E. Efstathiou, D. Rathkopf, J. Shelkey, E.Y. Yu, J. Alumkal, D. Hung, M. Hirmand, L. Seely, M.J. Morris, D.C. Danila, J. Humm, S. Larson, M. Fleisher, and C.L. Sawyers Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study Lancet 375 2010 1437 1446
34. H.I. Scher, K. Fizazi, F. Saad, M.E. Taplin, C.N. Sternberg, K. Miller, R. de Wit, P. Mulders, K.N. Chi, N.D. Shore, A.J. Armstrong, T.W. Flaig, A. Flechon, P. Mainwaring, M. Fleming, J.D. Hainsworth, M. Hirmand, B. Selby, L. Seely, and J.S. De Bono Increased survival with enzalutamide in prostate cancer after chemotherapy New England Journal of Medicine 367 2012 1187 1197
35. C.J. Ryan, and D.J. Tindall Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically Journal of Clinical Oncology 29 2011 3651 3658
36. M. Yamaoka, T. Hara, T. Hitaka, T. Kaku, T. Takeuchi, J. Takahashi, S. Asahi, H. Miki, A. Tasaka, and M. Kusaka Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys Journal of Steroid Biochemistry and Molecular Biology 129 2012 115 128
37. K.D. Courtney, and M.E. Taplin The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer Current Opinion in Oncology 24 2012 272 277
38. Clinical trials, www.clinicaltrials.gov, 2013.
39. Y. Li, S.C. Chan, L.J. Brand, T.H. Hwang, K.A. Silverstein, and S.M. Dehm Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines Cancer Research 73 2013 483 489
40. Y.C. Yang, L.G. Meimetis, A.H. Tien, N.R. Mawji, G. Carr, J. Wang, R.J. Andersen, and M.D. Sadar Spongian diterpenoids inhibit androgen receptor activity Molecular Cancer Therapeutics 12 2013 621 631
41. S. Fili, M. Karalaki, and B. Schaller Mechanism of bone metastasis: the role of osteoprotegerin and of the host-tissue microenvironment-related survival factors Cancer Letters 283 2009 10 19
42. H.L. Neville-Webbe, and R.E. Coleman Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease European Journal of Cancer 46 2010 1211 1222
43. J. Sturge, M.P. Caley, and J. Waxman Bone metastasis in prostate cancer: emerging therapeutic strategies Nature Reviews Clinical Oncology 8 2011 357 368
44. K. Fizazi, M. Carducci, M. Smith, R. Damiao, J. Brown, L. Karsh, P. Milecki, N. Shore, M. Rader, H. Wang, Q. Jiang, S. Tadros, R. Dansey, and C. Goessl Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study Lancet 377 2011 813 822
45. S. Nilsson, L. Franzen, C. Parker, C. Tyrrell, R. Blom, J. Tennvall, B. Lennernas, U. Petersson, D.C. Johannessen, M. Sokal, K. Pigott, J. Yachnin, M. Garkavij, P. Strang, J. Harmenberg, B. Bolstad, and O.S. Bruland Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study Lancet Oncology 8 2007 587 594 (Pubitemid 46995621)
46. R.M. Macklis, and A.O. Sartor New mechanistic insights into possible radiobiologic and pathophysiologic explanations for unexpectedly impressive outcomes data observed for hormone-refractary metastatic prostate cancer patients treated with radium 223 Journal of Clinical Oncology 30 2012 (suppl; abstr 10623), Ref Type: Abstract
47. R. Montironi, M. Scarpelli, A. Lopez-Beltran, and L. Cheng Editorial comment on: expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters European Urology 56 2009 846 847
48. J.B. Nelson, S.H. Nguyen, J.R. Wu-Wong, T.J. Opgenorth, D.B. Dixon, L.W. Chung, and N. Inoue New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade Urology 53 1999 1063 1069 (Pubitemid 29196330)
49. C. Nabhan, B. Parsons, E.Z. Touloukian, and W.M. Stadler Novel approaches and future directions in castration-resistant prostate cancer Annals of Oncology 22 2011 1948 1957
50. E.S. Kopetz, J.B. Nelson, and M.A. Carducci Endothelin-1 as a target for therapeutic intervention in prostate cancer Investigational New Drugs 20 2002 173 182 (Pubitemid 34627443)
51. M.A. Carducci, R.J. Padley, J. Breul, N.J. Vogelzang, B.A. Zonnenberg, D.D. Daliani, C.C. Schulman, A.A. Nabulsi, R.A. Humerickhouse, M.A. Weinberg, J.L. Schmitt, and J.B. Nelson Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial Journal of Clinical Oncology 21 2003 679 689 (Pubitemid 46621903)
52. M.A. Carducci, F. Saad, P.A. Abrahamsson, D.P. Dearnaley, C.C. Schulman, S.A. North, D.J. Sleep, J.D. Isaacson, and J.B. Nelson A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer Cancer 110 2007 1959 1966 (Pubitemid 350036854)
53. N.D. James, A. Caty, M. Borre, B.A. Zonnenberg, P. Beuzeboc, T. Morris, D. Phung, and N.A. Dawson Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial European Urology 55 2009 1112 1123
54. N.D. James, A. Caty, H. Payne, M. Borre, B.A. Zonnenberg, P. Beuzeboc, S. McIntosh, T. Morris, D. Phung, and N.A. Dawson Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized phase II trial BJU International 106 2010 966 973
55. J.B. Nelson, K. Fizazi, K. Miller, C. Higano, J.W. Moul, H. Akaza, T. Morris, S. McIntosh, K. Pemberton, and M. Gleave Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone Cancer 118 2012 5709 5718
56. K. Miller, J.W. Moul, M. Gleave, K. Fizazi, J.B. Nelson, T. Morris, F.E. Nathan, S. McIntosh, K. Pemberton, and C.S. Higano Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer Prostate Cancer and Prostatic Diseases 16 2013 187 192
57. D.L. Trump, H. Payne, K. Miller, J.S. de Bono, J. Stephenson, H.A. Burris III, F. Nathan III, M. Taboada, T. Morris, and A. Hubner Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer Prostate 71 2011 1264 1275
58. G. Zhou, and H. Levitsky Towards curative cancer immunotherapy: overcoming posttherapy tumor escape Clinical and Developmental Immunology 2012 2012 124187
59. L. Fong, and E.J. Small Immunotherapy for prostate cancer Current Urology Reports 7 2006 239 246 (Pubitemid 44624010)
60. E. Cha, and L. Fong Immunotherapy for prostate cancer: biology and therapeutic approaches Journal of Clinical Oncology 29 2011 3677 3685
61. E.J. Small, P.F. Schellhammer, C.S. Higano, C.H. Redfern, J.J. Nemunaitis, F.H. Valone, S.S. Verjee, L.A. Jones, and R.M. Hershberg Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer Journal of Clinical Oncology 24 2006 3089 3094 (Pubitemid 46638945)
62. P.W. Kantoff, T.J. Schuetz, B.A. Blumenstein, L.M. Glode, D.L. Bilhartz, M. Wyand, K. Manson, D.L. Panicali, R. Laus, J. Schlom, W.L. Dahut, P.M. Arlen, J.L. Gulley, and W.R. Godfrey Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer Journal of Clinical Oncology 28 2010 1099 1105
63. R.S. DiPaola, M. Plante, H. Kaufman, D.P. Petrylak, R. Israeli, E. Lattime, K. Manson, and T. Schuetz A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer Journal of Translational Medicine 4 2006 1
64. P. Specenier Ipilimumab in melanoma Expert Review of Anticancer Therapy 2012
65. R.A. Madan, M. Mohebtash, P.M. Arlen, M. Vergati, M. Rauckhorst, S.M. Steinberg, K.Y. Tsang, D.J. Poole, H.L. Parnes, J.J. Wright, W.L. Dahut, J. Schlom, and J.L. Gulley Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial Lancet Oncology 13 2012 501 508
66. W.L. Dahut, J.L. Gulley, P.M. Arlen, Y. Liu, K.M. Fedenko, S.M. Steinberg, J.J. Wright, H. Parnes, C.C. Chen, E. Jones, C.E. Parker, W.M. Linehan, and W.D. Figg Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer Journal of Clinical Oncology 22 2004 2532 2539 (Pubitemid 41103740)
67. D. Keizman, M. Zahurak, V. Sinibaldi, M. Carducci, S. Denmeade, C. Drake, R. Pili, E.S. Antonarakis, S. Hudock, and M. Eisenberger Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study Clinical Cancer Research 16 2010 5269 5276
68. B. Adesunloye, X. Huang, J.M. Ning, A. Ravi, J. Madan, and J. Beatson Dual antiangiogenic therapy using lenalidomide and bevacizumab with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) Journal of Clinical Oncology 30 2012 (suppl; abstr 4569), Ref Type: abstract
69. P. Carmeliet, and R.K. Jain Angiogenesis in cancer and other diseases Nature 407 2000 249 257
70. P. Carmeliet VEGF as a key mediator of angiogenesis in cancer Oncology 69 Suppl. 3 2005 4 10 (Pubitemid 41680947)
71. G. Di Lorenzo, W.D. Figg, S.D. Fossa, V. Mirone, R. Autorino, N. Longo, C. Imbimbo, S. Perdona, A. Giordano, M. Giuliano, R. Labianca, and S. De Placido Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study European Urology 54 2008 1089 1094
72. W.K. Kelly, S. Halabi, M. Carducci, D. George, J.F. Mahoney, W.M. Stadler, M. Morris, P. Kantoff, J.P. Monk, E. Kaplan, N.J. Vogelzang, and E.J. Small Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401 Journal of Clinical Oncology 30 2012 1534 1540
73. J. Hasskarl Sorafenib Recent Results Cancer Research 184 2010 61 70
74. J.B. Aragon-Ching, L. Jain, J.L. Gulley, P.M. Arlen, J.J. Wright, S.M. Steinberg, D. Draper, J. Venitz, E. Jones, C.C. Chen, W.D. Figg, and W.L. Dahut Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer BJU International 103 2009 1636 1640
75. E.K. Beardsley, S.J. Hotte, S. North, S.L. Ellard, E. Winquist, C. Kollmannsberger, S.D. Mukherjee, and K.N. Chi A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer Invest New Drugs 30 2012 1652 1659
76. Q.S. Chu Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors Expert Opinion on Biological Therapy 9 2009 263 271
77. G. Sonpavde, P.O. Periman, D. Bernold, D. Weckstein, M.T. Fleming, M.D. Galsky, W.R. Berry, F. Zhan, K.A. Boehm, L. Asmar, and T.E. Hutson Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy Annals of Oncology 21 2010 319 324
78. A.J. Zurita, D.J. George, N.D. Shore, G. Liu, G. Wilding, T.E. Hutson, M. Kozloff, P. Mathew, C.S. Harmon, S.L. Wang, I. Chen, E.C. Maneval, and C.J. Logothetis Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial Annals of Oncology 23 2012 688 694
79. D. Romero, C. O'Neill, A. Terzic, L. Contois, K. Young, B.A. Conley, R.C. Bergan, P.C. Brooks, and C.P. Vary Endoglin regulates cancer-stromal cell interactions in prostate tumors Cancer Research 71 2011 3482 3493
80. L.S. Rosen, H.I. Hurwitz, M.K. Wong, J. Goldman, D.S. Mendelson, W.D. Figg, S. Spencer, B.J. Adams, D. Alvarez, B.K. Seon, C.P. Theuer, B.R. Leigh, and M.S. Gordon A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer Clinical Cancer Research 18 2012 4820 4829
81. C. Pezaro, M.A. Rosenthal, H. Gurney, I.D. Davis, C. Underhill, M.J. Boyer, D. Kotasek, B. Solomon, and G.C. Toner An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer American Journal of Clinical Oncology 32 2009 338 341
82. E.J. Small, J. Fontana, N. Tannir, R.S. DiPaola, G. Wilding, M. Rubin, R.B. Iacona, and F.F. Kabbinavar A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer BJU International 100 2007 765 769 (Pubitemid 47360196)
83. G. Liu, Y.H. Chen, J. Kolesar, W. Huang, R. Dipaola, M. Pins, M. Carducci, M. Stein, G.J. Bubley, and G. Wilding Eastern cooperative oncology group phase II trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer Urologic Oncology 31 2013 211 218
84. Y.E. Whang, A.J. Armstrong, W.K. Rathmell, P.A. Godley, W.Y. Kim, R.S. Pruthi, E.M. Wallen, J.M. Crane, D.T. Moore, G. Grigson, K. Morris, C.P. Watkins, and D.J. George A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer Urologic Oncology 31 2013 82 86
85. M.T. Fleming, G. Sonpavde, M. Kolodziej, S. Awasthi, T.E. Hutson, D. Martincic, A. Rastogi, S.R. Rousey, R.E. Weinstein, M.D. Galsky, W.R. Berry, Y. Wang, K.A. Boehm, L. Asmar, M.A. Rauch, and T.M. Beer Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer Clinical Genitourinary Cancer 10 2012 6 14
86. C. Nabhan, D. Villines, T.V. Valdez, K. Tolzien, T.M. Lestingi, J.D. Bitran, S.M. Christner, M.J. Egorin, and J.H. Beumer Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer British Journal of Cancer 107 2012 592 597
87. I. Heidegger, A. Pircher, H. Klocker, and P. Massoner Targeting the insulin-like growth factor network in cancer therapy Cancer Biology & Therapy 11 2011 701 707
88. E. Seccareccia, and P. Brodt The role of the insulin-like growth factor-I receptor in malignancy: an update Growth Hormone & IGF Research 22 2012 193 199
89. M. Pollak The insulin and insulin-like growth factor receptor family in neoplasia: an update Nature Reviews Cancer 12 2012 159 169
90. K.N. Chi, M.E. Gleave, L. Fazli, S.L. Goldenberg, A. So, C. Kollmannsberger, N. Murray, A. Tinker, and M. Pollak A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer Clinical Cancer Research 18 2012 3407 3413
91. R. Kurzrock, S.I. Sherman, D.W. Ball, A.A. Forastiere, R.B. Cohen, R. Mehra, D.G. Pfister, E.E. Cohen, L. Janisch, F. Nauling, D.S. Hong, C.S. Ng, L. Ye, R.F. Gagel, J. Frye, T. Muller, M.J. Ratain, and R. Salgia Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer Journal of Clinical Oncology 29 2011 2660 2666
92. D.C. Smith, M.R. Smith, C. Sweeney, A.A. Elfiky, C. Logothetis, P.G. Corn, N.J. Vogelzang, E.J. Small, A.L. Harzstark, M.S. Gordon, U.N. Vaishampayan, N.B. Haas, A.I. Spira, P.N. Lara, C.C. Lin Jr., S. Srinivas, A. Sella, P. Schoffski, C. Scheffold, A.L. Weitzman, and M. Hussain Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial Journal of Clinical Oncology 31 2013 412 419
93. J.S. De Bono, S. Oudard, M. Ozguroglu, S. Hansen, J.P. Machiels, I. Kocak, G. Gravis, I. Bodrogi, M.J. Mackenzie, L. Shen, M. Roessner, S. Gupta, and A.O. Sartor Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
94. A. Heidenreich, H.J. Scholz, S. Rogenhofer, C. Arsov, M. Retz, S.C. Muller, P. Albers, J. Gschwend, M. Wirth, U. Steiner, K. Miller, E. Heinrich, L. Trojan, B. Volkmer, F. Honecker, C. Bokemeyer, B. Keck, B. Otremba, E. Ecstein-Fraisse, and D. Pfister Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme European Urology 63 2013 977 982